Table 1.
Pre–antiretroviral Therapy Characteristics of Adults With Human Immunodeficiency Virus and Pulmonary Tuberculosis
| Characteristic | Imaging Cohort (n = 48) |
Qualifying Combined Imaging and Parent Cohort (n = 63) |
|---|---|---|
| Female sex, n (%) | 26 (54%) | 23 (37%) |
| Age, mean (range) | 37 (22–54) | 37 (20–57) |
| Pre-ART CD4 T-cell count, median cells/µL (IQR) | 87 (48–191) | 118 (49–194)a |
| CD4 T-cell count >50 cells/µl, n (%) | 33 (69%) | 45 (74%)a |
| HIV viral load, median log10 copies/mL (IQR) | 5.1 (4.7–5.5) | 5.3 (4.8–5.8)a |
| Body mass index, median (IQR) | 18.8 (17.6–21.1) | 19.2 (18.4–21.4) |
| TB treatment to ART initiation interval, median days (IQR) | 21 (14–41) | 22 (15–38)a |
| Ever smoked, n (%) | 17 (35%) | 24 (38%) |
| Sputum culture positive, n (%) | 27 (56%) | 31 (49%) |
| Days to positivity among culture-positive subjects, median (IQR) | 14 (11–17) | 13 (8–15) |
| FEV1, L, median (IQR)b | 2.4 (1.9–2.8) | 2.4 (2.1–2.8) |
| FEV1, %, median (IQR)b | 79 (64–88) | 79 (64–90) |
| FVC, mL, median (IQR)b | 3.1 (2.5–3.6) | 3.2 (2.7–3.7) |
| FVC, %, median (IQR)b | 84 (70–97) | 86 (72–94) |
| FEV1/FVC ratio, median (IQR)b | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) |
| Percent of lung involved, median (IQR) | 19% (6–31%) | NA |
| Cavitation on CT scan, n (%) | 18 (33%) | NA |
| Mean SUV, median (IQR) | 1.6 (1.3–2.2) | NA |
| Max SUV, median (IQR) | 8.7 (5.3–13.9) | NA |
| CT hard volume, median mL (IQR) | 37 (24–113) | NA |
| Region of interest volume, median mL (IQR) | 464 (148–718) | NA |
| Total lung glycolytic activity, median (IQR) | 768.8 (197.8–1585.1) | NA |
| Log10 total lung glycolytic activity, median (IQR) | 2.9 (2.3–3.2) | NA |
Abbreviations: ART, antiretroviral therapy; CT, computed tomography; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; SUV, standard uptake value; TB, tuberculosis.
a n = 61.
b38 subjects in the imaging cohort completed usable spirometry at baseline.